FindTrial
Sign In

Clinical Profile Of Multiple Myeloma

Clinical Profile Of Multiple Myeloma With Special Focus On Serum LDH As a Response Marker

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035576
Enrollment
40
Registered
2021-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C900- Multiple myeloma

Interventions

None listed

Sponsors

Kasturba Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed and previously diagnosed untreated patients of MM coming to Kasturba hospital, Manipal will be included in the study. Diagnosis will be confirmed according to revised IMWG criteria

Exclusion criteria

Exclusion criteria: Patients of multiple myeloma who are already on treatment Patients with other co-existing malignancy

Design outcomes

Primary

MeasureTime frame
Evaluate the common clinical and laboratory features, stages, and outcome after primary treatment of patients with Multiple Myeloma and correlate LDH levels as a response markerTimepoint: Evaluate the common clinical and laboratory features, stage including serum ldh level at the time of diagnosis (baseline), and outcome after primary treatment of patients with Multiple Myeloma which will be after 4 months and correlate baseline LDH levels as a response marker—

Secondary

MeasureTime frame
correlate LDH levels as a response markerTimepoint: correlate pretreatment LDH levels as a response marker after primary treatment with 4 cycles of chemotherapy after 4 months—

Countries

India

Contacts

Public ContactGayatri Jawade

Associate professor ion department of general medicine

rmoorthi414@gmail.com9449615194

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026